GI Stool Testing Market by Product, Test, Application, End-use

Description

List of Tables

[183 Pages Report] The GI Stool Testing Market size was estimated at USD 651.69 million in 2023 and expected to reach USD 691.83 million in 2024, at a CAGR 6.67% to reach USD 1,024.26 million by 2030.

The GI (Gastrointestinal) stool testing market involves the analysis of fecal samples to diagnose infections, disorders, or diseases affecting the gastrointestinal tract. Rising cases of diseases such as colorectal cancer, IBD, and infections increase the demand for effective diagnostic methods. Technological innovations in testing technologies enhance the accuracy and speed of test results, appealing to both healthcare providers and patients. Increased health awareness and an improved understanding of the importance of early diagnosis contribute to market growth. However, stringent regulations governing diagnostic testing can delay product launches and influence market dynamics. Lack of healthcare infrastructure may challenge market growth in lesser-developed regions. Moreover, the detection of genetic markers in fecal samples can offer substantial growth opportunities. Leveraging artificial intelligence and machine learning for better data analysis and result accuracy presents a significant opportunity for market expansion.

KEY MARKET STATISTICS
Base Year [2023]	USD 651.69 million
Estimated Year [2024]	USD 691.83 million
Forecast Year [2030]	USD 1,024.26 million
CAGR (%)	6.67%

Regional Insights

In the Americas region, particularly in the United States and Canada, the prevalence of gastrointestinal disorders such as IBS, Crohn's disease, and colorectal cancer has significantly driven the demand for GI stool testing. High awareness about health and preventive care, comprehensive insurance coverage, and robust healthcare infrastructure contribute to the sophistication of the GI stool testing market. EU countries exhibit a strong market for GI stool tests owing to high healthcare standards and prevalent screening programs for colorectal cancer. Countries such as France, Germany, and the UK emphasize preventative healthcare, thereby facilitating substantial market growth in this region. Middle East countries such as Saudi Arabia and UAE are rapidly adopting modern healthcare practices, including the use of sophisticated diagnostics tools for GI disorders. However, in parts of Africa, limited healthcare infrastructure and lower health literacy levels constrain the market. In the Asia-Pacific region, China's rapidly growing healthcare sector, bolstered by governmental reforms aimed at improving healthcare access, presents significant opportunities for the GI stool testing market. Aging population dynamics invite higher incidences of gastrointestinal illnesses, further strengthening the market scope in Japan. India's market is nascent but growing rapidly, driven by increasing awareness and improving healthcare infrastructure.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the GI Stool Testing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
- Rising incidences of gastrointestinal disorders and diseases across the world
- Efforts by governments and foundations to raise awareness for gastrointestinal health

Market Restraints
- Issues associated with product recalls in GI stool testing

Market Opportunities
- Technological advancements in GI stool testing methods to develop more accurate and less invasive tools
- Reforms and supportive measures in healthcare policies

Market Challenges
- Challenges with product standardization and compatibility

Market Segmentation Analysis
- Product: Preference towards GI stool analyzers due to their speed and accuracy in diagnostics
- End-Users: Expanding application of GI Stool Testing in diagnostic centers

Market Disruption Analysis
Porter's Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the GI Stool Testing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the GI Stool Testing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

FDA Approval of ColoSense, A Breakthrough in Noninvasive Colorectal Cancer Screening

Geneoscopy, Inc., an innovator in gastrointestinal health diagnostics, announced FDA approval for its groundbreaking colorectal cancer (CRC) screening test, ColoSense. Suitable for adults aged 45 and older at average CRC risk, ColoSense stands out as the first noninvasive test employing RNA biomarkers to dynamically assess disease activity without the variability seen in other age-dependent tests. This approval followed the impressive results of the CRC-PREVENT trial, which showed ColoSense's high sensitivity for detecting CRC and 100% in early-stage detection, where the disease is highly treatable. [Published On: 2024-05-06]

Evaluation of ColoTest, A Consumer-Friendly, At-Home Screening Tool for Early Detection of Gastrointestinal Conditions

ColoTest, an over-the-counter immunochemical fecal occult blood test, is marketed by Reese Pharmaceutical for at-home use. This kit is designed to detect hidden blood in stool, indicative of serious conditions such as colorectal cancer and gastrointestinal disorders, providing a test cassette, sample collection tube, and necessary instructions for user convenience. [Published On: 2024-02-27]

Geneoscopy and Labcorp Partnership Elevates Access to Innovative Colorectal Cancer Screening

Geneoscopy Inc., has announced a strategic partnership with Labcorp for distribution of Geneoscopy's revolutionary at-home colorectal cancer (CRC) screening test, which is awaiting FDA approval. Upon approval, the test will be available through Labcorp, bolstering the convenience and accessibility of CRC screening. The test utilizes a multi-target stool RNA biomarker panel, capable of identifying both precancerous lesions and colorectal cancer, showing high sensitivity in clinical trials. [Published On: 2023-11-14]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the GI Stool Testing Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the GI Stool Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Bio-Rad Laboratories, Inc., bioMerieux SA, Cardinal Health, Cenogenics Corporation, CTK Biotech, Inc., Danaher Corporation, Diagnostic Solutions Laboratory, LLC, DiaSorin S.p.A., Eiken Chemical Co., Ltd., Emes Software, LLC, Epitope Diagnostics Inc., Geisinger Medical Laboratories, Genova Diagnostics Inc., Helena Laboratories Corporation, Hologic Inc., Lauriston Laboratories Ltd, Meridian Bioscience Inc., Pinnacle BioLabs, Polymedco, LLC, Quest Diagnostics, QuidelOrtho Corporation, ScheBo Biotech AG, and Siemens Healthineers.

Market Segmentation & Coverage

This research report categorizes the GI Stool Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Analyzers
- Consumables

Test
- Bacteria Test
- Fecal Biomarkers Test
  - Transferrin Assays
  - Tumor M2-PK Stool Test

Occult Blood Test
- Guaiac FOB Stool Test
- Immuno FOB Agglutination Test
- Immuno FOB ELISA Test
- Lateral Flow Immuno FOB Test

Ova and Parasites Test

Application
- Cancer
- Gastroesophageal Reflux Disease
- Infection
- Inflammatory Bowel Disease

End-use
- Diagnostic Centers
- Homecare Settings
- Hospitals & Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

Product Code: MRR-CB04E056547A

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising incidences of gastrointestinal disorders and diseases across the world
  - 5.1.1.2. Efforts by governments and foundations to raise awareness for gastrointestinal health
- 5.1.2. Restraints
  - 5.1.2.1. Issues associated with product recalls in GI stool testing
- 5.1.3. Opportunities
  - 5.1.3.1. Technological advancements in GI stool testing methods to develop more accurate and less invasive tools
  - 5.1.3.2. Reforms and supportive measures in healthcare policies
- 5.1.4. Challenges
  - 5.1.4.1. Challenges with product standardization and compatibility
5.2. Market Segmentation Analysis
- 5.2.1. Product: Preference towards GI stool analyzers due to their speed and accuracy in diagnostics
- 5.2.2. End-Users: Expanding application of GI Stool Testing in diagnostic centers
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. GI Stool Testing Market, by Product

6.1. Introduction
6.2. Analyzers
6.3. Consumables

7. GI Stool Testing Market, by Test

7.1. Introduction
7.2. Bacteria Test
7.3. Fecal Biomarkers Test
7.4. Occult Blood Test
7.5. Ova and Parasites Test

8. GI Stool Testing Market, by Application

8.1. Introduction
8.2. Cancer
8.3. Gastroesophageal Reflux Disease
8.4. Infection
8.5. Inflammatory Bowel Disease

9. GI Stool Testing Market, by End-use

9.1. Introduction
9.2. Diagnostic Centers
9.3. Homecare Settings
9.4. Hospitals & Clinics

10. Americas GI Stool Testing Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific GI Stool Testing Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa GI Stool Testing Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. FDA Approval of ColoSense, A Breakthrough in Noninvasive Colorectal Cancer Screening
- 13.3.2. Evaluation of ColoTest, A Consumer-Friendly, At-Home Screening Tool for Early Detection of Gastrointestinal Conditions
- 13.3.3. Geneoscopy and Labcorp Partnership Elevates Access to Innovative Colorectal Cancer Screening
13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio